Dr. Geynisman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Suite N713
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-214-3779
Summary
- Daniel Geynisman, MD is an oncologist based in Philadelphia, PA with a subspecialty in Genitourinary Oncology. He received his fellowship in Hematology and Medical Oncology from the University of Chicago and completed his residency in Internal Medicine at UPMC Medical Education, after graduating from the University of Pittsburgh School of Medicine. Dr. Geynisman is experienced in treating conditions such as adrenal neoplasms, urologic oncology, kidney cancer, bladder cancer, and testicular cancer. Furthermore, he has made significant contributions to the field with numerous published articles in esteemed medical publications. He has also carried out clinical trials, notably 'A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer.'
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2010 - 2013
UPMC Medical EducationResidency, Internal Medicine, 2006 - 2010
University of Pittsburgh School of MedicineClass of 2006
Certifications & Licensure
PA State Medical License 2006 - 2026
IL State Medical License 2010 - 2014
American Board of Internal Medicine Medical Oncology
American Board of Medical OncologyMedical Oncology
Clinical Trials
- A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer Start of enrollment: 2020 Dec 01
Publications & Presentations
PubMed
- Comparison of Outcomes Between African American and European American Patients With Metastatic Clear Cell Renal Cell Carcinoma Receiving Immune Checkpoint Inhibitors.Jasmeet Kaur, Jill S Hasler, Elizabeth A Handorf, Matthew R Zibelman, Fern Anari
Clinical Genitourinary Cancer. 2025-04-01 - Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).Daniel M Geynisman, Philip H Abbosh, Eric Ross, Matthew R Zibelman, Pooja Ghatalia
Journal of Clinical Oncology. 2025-03-20 - 1 citationsImpact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.Stephanie A Berg, Salvatore La Rosa, Tian Zhang, Phillip M Pierorazio, Laurence Albiges
Urologic Oncology. 2025-03-01
Press Mentions
Daniel Geynisman on a Risk-Adapted Approach for Bladder Preservation in MIBCFebruary 27th, 2025- Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBCDecember 23rd, 2024
- Daniel M. Geynisman, MD, Named New JNCCN Editor-in-ChiefMay 17th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
